• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    West Pharmaceutical Services (NY: WST )

    330.30 +15.53 (+4.93%)
    Streaming Delayed Price Updated: 12:22 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about West Pharmaceutical Services

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Balancing Dividends and Fundamentals: The Case of NYSE:WST.
    Analyzing WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s Dividend Potential. 
    Via Chartmill
    West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
    West Pharmaceutical Services reported Q3 adjusted EPS of $1.85, beating estimates, with $746.9 million in sales. Updated 2024 guidance reflects higher EPS and sales. 
    Via Benzinga
    UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Earnings Outlook For West Pharmaceutical Servs
    Via Benzinga
    (WST) - Analyzing West Pharmaceutical Servs's Short Interest
    Via Benzinga
    Exploring NYSE:WST's dividend characteristics.
    Exploring WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s dividend characteristics. 
    Via Chartmill
    Is NYSE:WST a Good Fit for Dividend Investing?
    Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) qualifies as a good dividend investing stock. 
    Via Chartmill
    Balancing Dividends and Fundamentals: The Case of NYSE:WST.
    Why the dividend investor may take a look at WEST PHARMACEUTICAL SERVICES (NYSE:WST). 
    Via Chartmill
    Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    S&P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday's Top Movers
    S&P 500 and Nasdaq 100 indices gain for seventh straight day, marking best weekly performance since October 2023 on positive economic data. SPY and QQQ close with modest daily gains while DIA has best... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio?
    Top 10 worst performers last week: EW (-28.05%), F (-19.12%), STM (-17.60%), TER (-16.25%), MBLY (-14.61%), STLA (-13.07%), VRT (-12.04%), SMCI (-11.68%), WST (-11.37%), DELL (-11.26%), UPS (-10.96%),... 
    Via Benzinga
    Why NYSE:WST is a Top Pick for Dividend Investors.
    Exploring WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s dividend characteristics. 
    Via Chartmill
    How Is The Market Feeling About West Pharmaceutical Servs?
    Via Benzinga
    Uncovering Dividend Opportunities with NYSE:WST.
    Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) qualifies as a good dividend investing stock. 
    Via Chartmill
    Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    WST Stock Earnings: West Pharmaceutical Servs Misses EPS, Misses Revenue for Q2 2024
    WST stock results show that West Pharmaceutical Servs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Peering Into West Pharmaceutical Servs's Recent Short Interest
    Via Benzinga
    How Is The Market Feeling About West Pharmaceutical Servs?
    Via Benzinga
    Why the dividend investor may take a look at NYSE:WST.
    Via Chartmill
    (WST) - Analyzing West Pharmaceutical Servs's Short Interest
    Via Benzinga
    WST Stock Earnings: West Pharmaceutical Servs Beats EPS, Beats Revenue for Q1 2024
    WST stock results show that West Pharmaceutical Servs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Exploring NYSE:WST's dividend characteristics.
    Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) is a Top Pick for Dividend Investors. 
    Via Chartmill
    3 Pharma Stocks to Sell in March Before They Crash & Burn
    Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
    Via InvestorPlace
    Analyzing NYSE:WST's Dividend Potential.
    Is WEST PHARMACEUTICAL SERVICES (NYSE:WST) a Good Fit for Dividend Investing? 
    Via Chartmill
    S&P Reclaims 5,000 As Disappointing Retail Sales Put Fed Cuts Back On Track, Small Caps Shine: What's Driving Markets Thursday?
    US stocks surge on strong earnings and speculation of Fed rate cuts. S&P 500 rebounds past 5000, Nasdaq 100 pauses. Small caps outperform. Tesla, Wells Fargo, and CBRE rally on positive news while Deer... 
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    (WST) - Analyzing West Pharmaceutical Servs's Short Interest
    Via Benzinga
    West Pharmaceutical Sets 2024 EPS Guidance at $7.50-$7.75
    WST reported a robust fourth-quarter with net sales of $732.0 million, marking a 3.3% increase. 
    Via Talk Markets
    Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
    Via Benzinga
    West Pharmaceutical's 2024 Outlook Cautious, Analysts Remain Optimistic
    West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth,... 
    Via Benzinga
    Earnings Scheduled For February 15, 2024
    Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.